NASA Hospitals is building India's premier asset-light specialty healthcare platform. The operating thesis is distinctive: rather than greenfield hospital construction, NASA acquires and professionalises distressed mid-market hospitals (typically 75-100 beds) and converts them from traditional general-care models into single-specialty focused centres — Neuro, Spine, Ortho, and Critical Care.

The platform has a proven track record: 150 beds across 3 operating hospitals with a 12–18 month turnaround playbook. The $40M raise funds scaling to 1,000 beds over 5 years, targeting 25-30% ROCE and an exit at 15-30× EBITDA via IPO or strategic sale.

The Alpha is capturing the arbitrage between corporate hospital pricing and unorganised supply — patients get corporate-grade clinical outcomes at 20-30% lower cost; investors get a capital-efficient platform engineered for superior unit economics and rapid scaling. The raised capital is fuel for growth — acquiring distressed targets and building market share — not for real estate.

NASA's operating playbook targets the 75-100 bed mid-market segment with a single-specialty focused model across four verticals:

• Neuro — neurology, neurosurgery, stroke care, neuro-intervention
• Spine — spine surgery, minimally invasive procedures, pain management
• Ortho — orthopaedic surgery, joint replacement, sports medicine
• Critical Care — ICU, emergency medicine, trauma, high-acuity services

The 12-18 month turnaround playbook brings distressed targets from negative EBITDA to 25%+ EBITDA margins through four operating levers: (1) specialty focus driving case-mix improvement and ARPOB expansion; (2) bulk procurement cost reduction (~12%); (3) elimination of related-party-transaction markups; (4) capital-structure refinancing at institutional rates.

NASA's lead pipeline acquisition is Asterix Hospitals, Hyderabad — a 150-bed distressed secondary-care platform positioned for turnaround + roll-up to a 500-bed Hyderabad platform. Key terms:

• 80% acquisition at ₹55 Cr equity / ₹80 Cr EV (~11.8× FY26 EBITDA) — a 30% discount to sector (Apollo/Max trade at 15-16× stabilised EBITDA).
• Capital stack: PE 49% / NASA 31% / Asterix promoters retain 20% for alignment.
• Use of equity: ₹10 Cr promoter buyout · ₹15 Cr debt refinancing (eliminates ₹24.4 Cr debt + saves ₹3.8 Cr annual interest) · ₹10 Cr working capital (normalise DSO 90→60 days) · ₹5 Cr capex (CT/ICU upgrades) · ₹15 Cr consolidation of NASA's existing 300-bed platform.
• Value creation bridge: FY26 EBITDA ₹6.8 Cr → FY29 EBITDA ₹27 Cr (at 500-bed scale).
• Exit target: IPO at 16-18× multiple producing 2.8–3.2× MoIC, 26-30% IRR.